MX2021015534A - Composiciones y metodos para el tratamiento de infecciones fungicas. - Google Patents

Composiciones y metodos para el tratamiento de infecciones fungicas.

Info

Publication number
MX2021015534A
MX2021015534A MX2021015534A MX2021015534A MX2021015534A MX 2021015534 A MX2021015534 A MX 2021015534A MX 2021015534 A MX2021015534 A MX 2021015534A MX 2021015534 A MX2021015534 A MX 2021015534A MX 2021015534 A MX2021015534 A MX 2021015534A
Authority
MX
Mexico
Prior art keywords
defensin
analogs
effect
immune system
compositions
Prior art date
Application number
MX2021015534A
Other languages
English (en)
Inventor
Dat Tran
Justin B Schaal
Michael E Selsted
Virginia Basso
Original Assignee
The Univ Of Southern California Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Southern California Star filed Critical The Univ Of Southern California Star
Publication of MX2021015534A publication Critical patent/MX2021015534A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se han desarrollado nuevos péptidos análogos de una ?-defensina que proporcionan un efecto bifásico en el tratamiento de la enfermedad fúngica diseminada y/o el choque séptico asociado. Estos análogos son activos en concentraciones por debajo de las necesarias para proporcionar un efecto fungicida, y funcionan movilizando inicialmente las células efectoras del sistema inmunológico para dirigirse al organismo infeccioso seguido de la regulación del sistema inmunológico para regular negativamente la respuesta inflamatoria. Estos nuevos análogos de ?-defensina son protectores en concentraciones en las que las ?-defensinas de origen natural no tienen un efecto aparente, e incluyen un conjunto básico de características estructurales y de secuencia que no se encuentran en las ?-defensinas nativas.
MX2021015534A 2019-06-26 2020-06-26 Composiciones y metodos para el tratamiento de infecciones fungicas. MX2021015534A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867000P 2019-06-26 2019-06-26
PCT/US2020/039865 WO2020264328A1 (en) 2019-06-26 2020-06-26 Compositions and methods for treatment of fungal infections

Publications (1)

Publication Number Publication Date
MX2021015534A true MX2021015534A (es) 2022-04-20

Family

ID=74042848

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021015534A MX2021015534A (es) 2019-06-26 2020-06-26 Composiciones y metodos para el tratamiento de infecciones fungicas.
MX2021015816A MX2021015816A (es) 2019-06-26 2020-06-26 Nuevos analogos de teta-defensina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015816A MX2021015816A (es) 2019-06-26 2020-06-26 Nuevos analogos de teta-defensina.

Country Status (11)

Country Link
US (4) US11021518B2 (es)
EP (2) EP3990472A4 (es)
JP (2) JP2022552925A (es)
KR (2) KR20220042129A (es)
CN (2) CN114080394A (es)
AU (2) AU2020302077C1 (es)
BR (2) BR112021026317A8 (es)
CA (2) CA3143032A1 (es)
IL (2) IL289236A (es)
MX (2) MX2021015534A (es)
WO (2) WO2020264328A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552925A (ja) * 2019-06-26 2022-12-21 イー． セルステッド、マイケル 真菌感染症の治療のための組成物及び方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916872A (en) * 1996-07-24 1999-06-29 Intrabiotics Pharmaceuticals, Inc. Cyclic peptides having broad spectrum antimicrobial activity
AU5153598A (en) * 1997-10-27 1999-05-17 Intrabiotics Pharmaceuticals, Inc. Cyclic peptides having broad spectrum antimicrobial activity
US6335318B1 (en) * 1999-05-10 2002-01-01 The Regents Of The University Of California Antimicrobial theta defensins and methods of using same
US20030022829A1 (en) 2001-03-30 2003-01-30 Wendy Maury Novel antiviral activities primate theta defensins and mammalian cathelicidins
US7119070B2 (en) * 2002-04-30 2006-10-10 The Regents Of The University Of California Antimicrobial theta defensins, analogs thereof, and methods of use
DE10226216A1 (de) * 2002-06-13 2003-12-24 Bayer Ag Behandlung von schweren Infektionen und septischem Schock
GB0300718D0 (en) 2003-01-13 2003-02-12 Ares Trading Sa Proteins
US20080255052A1 (en) * 2004-12-23 2008-10-16 The Regents Of The University Of California Immunologic regulation by theta defensins
WO2007044998A1 (en) 2005-10-12 2007-04-19 The Regents Of The University Of California Retrocyclins: antiviral and antimicrobial peptides
US7521535B2 (en) 2006-09-20 2009-04-21 The Board Of Regents For Oklahoma State University Anti-microbial defensin-related peptides and methods of use
CA2745499A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
BR112013030874B8 (pt) * 2011-06-02 2021-09-14 Univ California Uso de uma theta-defensina ou análogo da mesma para tratar uma condição inflamatória crônica
US9394561B2 (en) 2011-12-07 2016-07-19 National Research Council Of Canada Cyclic peptide production
WO2013130767A1 (en) 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
US10329550B2 (en) 2014-02-14 2019-06-25 Lysando Ag Antimicrobial agents
EP3180431A1 (en) 2014-08-11 2017-06-21 Miti Biosystems GmbH Cyclic peptides expressed by a genetic package
ES2710973T3 (es) 2014-08-29 2019-04-29 Ceinge Biotecnologie Avanzate S C A R L Análogos de las defensinas beta cíclicas para el tratamiento de infecciones
JP2022552925A (ja) * 2019-06-26 2022-12-21 イー． セルステッド、マイケル 真菌感染症の治療のための組成物及び方法

Also Published As

Publication number Publication date
JP2022552925A (ja) 2022-12-21
EP3990472A1 (en) 2022-05-04
BR112021026216A8 (pt) 2022-12-13
WO2020264328A1 (en) 2020-12-30
AU2020302077A1 (en) 2022-01-20
CA3144279A1 (en) 2020-12-30
BR112021026216A2 (pt) 2022-07-19
EP3990471A1 (en) 2022-05-04
KR20220044947A (ko) 2022-04-12
US20200407400A1 (en) 2020-12-31
AU2020302913A1 (en) 2022-01-27
MX2021015816A (es) 2022-04-18
CN114080394A (zh) 2022-02-22
US20230072433A1 (en) 2023-03-09
WO2020264389A1 (en) 2020-12-30
BR112021026317A2 (pt) 2022-04-12
AU2020302913B2 (en) 2023-02-23
US20200407399A1 (en) 2020-12-31
IL289236A (en) 2022-02-01
EP3990471A4 (en) 2023-07-12
AU2020302077C1 (en) 2023-11-30
AU2020302077B2 (en) 2023-08-31
AU2020302077A8 (en) 2022-05-12
US11021518B2 (en) 2021-06-01
CN114072415A (zh) 2022-02-18
EP3990472A4 (en) 2023-07-12
US11427617B2 (en) 2022-08-30
BR112021026317A8 (pt) 2022-12-13
JP2022538854A (ja) 2022-09-06
KR20220042129A (ko) 2022-04-04
US20210261623A1 (en) 2021-08-26
CA3143032A1 (en) 2020-12-30
IL289238A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
PH12017501757A1 (en) A novel paenibacillus strain, antifungal compounds, and methods for their use
MA44322A (fr) Compositions comprenant des souches bactériennes
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
MA42471B1 (fr) Compositions comprenant des souches bactériennes
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
BR112018010024A2 (pt) compostos e composições úteis no tratamento de distúrbios relacionados a ntrk
MX2017004780A (es) Nuevos peptidos inmunogenos.
MX2022015248A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
EA201692292A1 (ru) Соединения и композиции для стимулирования хондрогенеза
NZ754020A (en) Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
WO2017214170A3 (en) Baff-r antibodies and uses thereof
JOP20180094A1 (ar) مركب حلقي غير متجانس كمثبط بروتين كيناز
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
UA120999C2 (uk) Естери оксаборолу та їх використання
MX2023001538A (es) Composiciones y metodos para inhibir la expresion de lpa.
WO2016048861A3 (en) Heterocyclic compounds and use thereof
MX2021015534A (es) Composiciones y metodos para el tratamiento de infecciones fungicas.
CL2023002393A1 (es) Anticuerpos anti-cd30l y usos de estos
WO2015195684A3 (en) Small molecule anti-scarring agents
MX2022016239A (es) Composiciones y metodos para el tratamiento de infecciones fungicas.
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
WO2016122943A3 (en) Compounds, compositions, and methods for using hla-f
MX2016015574A (es) Composiciones esterilizadas de las proteinas ivig y kh para modular los linfocitos y tratar el virus de la hepatitis b.